BRIEF-Janssen says Health Canada approves Imbruvica for treatment of chronic lymphocytic leukemia

Wed Jul 20, 2016 8:19am EDT
 
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

July 20 (Reuters) - Johnson & Johnson :

* Health Canada approves Imbruvica (ibrutinib) for first-line treatment of chronic lymphocytic leukemia Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)